Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Hutchison China Meditech looks to first drug approval this year

Simon To, chairman, said: "In our Innovation Platform, we have progressed our deep portfolio of eight clinical drug candidates"
Scanner
Chi-Med has eight trials ongoing

AIM-listed cancer drug developer Hutchison China MediTech Limited (LON:HCM) expects this year will see fruquintinib become China’s first approved Tyrosine-Kinase inhibitor (TKI).

TKIs inhibit cancer cells’ ability to adapt and fruquintinib successfully passed a phase III study in colorectal cancer last year.

READ: Hutchison China MediTech kicks off first human trial for potential new cancer drug

A new drug application was submitted to China’s Center for Drug Evaluation of the CFDA in June 2017 and is undergoing technical reviews and manufacturing inspections.

Trials using fruquintinib, where Eli Lily is the Chi-Med’s partner, are also underway for gastric cancer and various stages of non-small cell lung cancer.

A second TKI, Savolitinib, is also going through clinical trials as a combination with AstraZeneca’s lung cancer treatments Tagrisso and Iressa.

These drugs are for patients suffering mutations on a gene called EGFR.

All told Chi-Med has six phase III trials either ongoing or enrolling at present and eight in total.

Simon To, chairman, said: "In our Innovation Platform, we have progressed our deep portfolio of eight clinical drug candidates, now in active or completing clinical trials in 36 TPPs around the world. 

“Two major milestones were the formal NDA submission for fruquintinib in CRC in China; and the initiation of our first global Phase III registration study of savolitinib in c-MET-driven metastatic PRCC. 

“We also presented positive Phase Ib/II data at major scientific conferences on savolitinib in PRCC, NSCLC and gastric cancer; fruquintinib in NSCLC and gastric cancer; sulfatinib in NET and thyroid cancer; and theliatinib in esophageal cancer, all positioning us well for 2018.”

Revenues in 2017 rose by 12% to $241.2mln (2016: US$216.1mln), with a net loss of US$26.7mln (US$11.7mln) after US$88mln spent on R&D.

Cash at the year-end was US$480mln after the company raised US$293mln when it joined Nasdaq late last year. 

View full HCM profile View Profile

Hutchison China MediTech Limited Timeline

Related Articles

scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
numerous pills
March 23 2018
Genervon is on the lookout for pharma partners to help advance its GM6 drug, which takes aim at a range of deadly diseases hitting the central nervous system
couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use